Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA;
Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Genes Dev. 2023 Oct 1;37(19-20):913-928. doi: 10.1101/gad.351085.123. Epub 2023 Nov 6.
Addiction to the WRN helicase is a unique vulnerability of human cancers with high levels of microsatellite instability (MSI-H). However, while prolonged loss of WRN ultimately leads to cell death, little is known about how MSI-H cancers initially respond to acute loss of WRN-knowledge that would be helpful for informing clinical development of WRN targeting therapy, predicting possible resistance mechanisms, and identifying useful biomarkers of successful WRN inhibition. Here, we report the construction of an inducible ligand-mediated degradation system in which the stability of endogenous WRN protein can be rapidly and specifically tuned, enabling us to track the complete sequence of cellular events elicited by acute loss of WRN function. We found that WRN degradation leads to immediate accrual of DNA damage in a replication-dependent manner that curiously did not robustly engage checkpoint mechanisms to halt DNA synthesis. As a result, WRN-degraded MSI-H cancer cells accumulate DNA damage across multiple replicative cycles and undergo successive rounds of increasingly aberrant mitoses, ultimately triggering cell death. Of potential therapeutic importance, we found no evidence of any generalized mechanism by which MSI-H cancers could adapt to near-complete loss of WRN. However, under conditions of partial WRN degradation, addition of low-dose ATR inhibitor significantly increased their combined efficacy to levels approaching full inactivation of WRN. Overall, our results provide the first comprehensive view of molecular events linking upstream inhibition of WRN to subsequent cell death and suggest that dual targeting of WRN and ATR might be a useful strategy for treating MSI-H cancers.
WRN 解旋酶成瘾是具有高水平微卫星不稳定 (MSI-H) 的人类癌症的独特脆弱性。然而,虽然 WRN 的长期缺失最终会导致细胞死亡,但对于 MSI-H 癌症最初如何对 WRN 的急性缺失做出反应,我们知之甚少——这对于为 WRN 靶向治疗的临床开发提供信息、预测可能的耐药机制以及识别成功抑制 WRN 的有用生物标志物很有帮助。在这里,我们构建了一种诱导配体介导的降解系统,其中内源性 WRN 蛋白的稳定性可以快速且特异性地进行调节,使我们能够追踪由 WRN 功能急性缺失引发的完整细胞事件序列。我们发现,WRN 降解会导致以复制依赖性方式立即积累 DNA 损伤,但奇怪的是,这种损伤不会强烈激活检查点机制来停止 DNA 合成。结果,WRN 降解的 MSI-H 癌细胞在多个复制周期中积累 DNA 损伤,并经历连续多轮越来越异常的有丝分裂,最终导致细胞死亡。具有潜在治疗意义的是,我们没有发现任何证据表明 MSI-H 癌症可以适应 WRN 近乎完全缺失的一般机制。然而,在 WRN 部分降解的情况下,添加低剂量 ATR 抑制剂可显著提高其联合疗效,使其接近完全失活 WRN 的水平。总体而言,我们的研究结果提供了将 WRN 上游抑制与随后的细胞死亡联系起来的分子事件的全面视图,并表明 WRN 和 ATR 的双重靶向可能是治疗 MSI-H 癌症的一种有用策略。